New inhaler shows promise for COPD in early trial

NCT ID NCT07252908

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental inhaled powder called TQC3721 in 195 people with moderate to severe COPD. The goal was to see if it improves lung function and is safe compared to a placebo. Researchers measured changes in breathing capacity over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQC3721 inhalation powder
What this could lead to: If successful, this could lead to a new inhaled treatment option to help control COPD symptoms and improve lung function.
What could go wrong: This is an early-phase trial with only 195 participants, so results may not apply to everyone. The drug may not show meaningful benefit over placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE

Contacts and locations

Locations

Affiliated Hospital Of ChengDu University

Chengdu, Sichuan, 610081, China
Chengdu Fifth People's Hospital

Chengdu, Sichuan, 610044, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China
Guigang People's Hospital

Guigang, Guangxi, 537100, China
Heze Municipal Hospital

Heze, Shandong, 274000, China
Jiangmen Central Hospital

Jiangmen, Guangdong, 529000, China
Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, 330006, China
Jiujiang First People's Hospital

Jiujiang, Jiangxi, 332000, China
Linfen People's Hospital

Linfen, Shanxi, 41000, China
Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210000, China
Nuclear Industry 416 Hospital

Chengdou, Sichuan, 610051, China
Puyang Oilfield General Hospital

Puyang, Henan, 457001, China
Shanghai JiaoTong University of medicine Ruijin Hospital

Shanghai, Shanghai Municipality, 20025, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
Siping Central People's Hospital

Siping, Jilin, 136099, China
Suining Central Hospital

Suining, Sichuan, 629000, China
Taizhou central hospital (Taizhou university hospital）

Taizhou, Zhejiang, 31800, China
The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU

Wenzhu, Zhejiang, 325027, China
The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010000, China
The Fourth Central Hospital of Tianjin

Tianjin, Tianjin Municipality, 300140, China
The People's Hospital of Liuyang

Changsha, Hunan, 410000, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chognqing, 400010, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
West China Hospital of Sichuan University

Chengdu, Sichuan, Sichuan 610044, China
Xiangtan County People's Hospital

Xiangtan, Hunan, 411200, China
Yibin Second People's Hospital

Yibin, Sichuan, 644000, China
Yichang Central People's Hospital

Yichang, Hubei, 443003, China
Yixing People'S Hospital

Wuxi, Jiangsu, 214000, China
Zunyi Medical University Affiliated Hospital

Zunyi, Guizhou, 563000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.